How can drug discovery for psychiatric disorders be improved?
The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Psychiatric disorders such as depression, anxiety and schizophrenia are leading causes of disability worldwide, and have a huge societal impact. However, despite the clear need for better therapies, and major advances in the understanding of the molecular basis of these disorders in recent years, efforts to discover and develop new drugs for neuropsychiatric disorders, particularly those that might revolutionize disease treatment, have been relatively unsuccessful. A multidisciplinary approach will be crucial in addressing this problem, and in the first Advances in Neuroscience for Medical Innovation symposium, experts in multiple areas of neuroscience considered key questions in the field, in particular those related to the importance of neuronal plasticity. The discussions were used as a basis to propose steps that can be taken to improve the effectiveness of drug discovery for psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mechanistic heterogeneity that potentially underlies the existing classification scheme might be limiting our ability to clarify etiology and identify novel therapeutics for several psychiatric illnesses (3).”
From Distinct neuropsychological subgroups in typically developing youth inform heterogeneity in children with ADHD (2012) · cites this paper as [3]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Neuronal Oscillations in Cortical Networks
Buzsáki, G., & Draguhn, A. (2004) · Science · doi:10.1126/science.1099745 · Cited by 6,576
Self-citationDeep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Self-citationMayberg, H. S., Liotti, M., Brannan, S. K., McGinnis, S., Mahurin, R. K., Jerabek, P. A., Silva, J. A., Tekell, J. L., Martin, C. C., Lancaster, J. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.675 · Cited by 2,416
Self-citationChanges in grey matter induced by training
Draganski, B., Gaser, C., Busch, V., Schuierer, G., Bogdahn, U., & May, A. (2004) · Nature · doi:10.1038/427311a · Cited by 2,373 · cited 1×
“Specific focal structural changes have been found; for example, related to visuo-spatial memory usage in London taxi-drivers and in training motor skill”
BackgroundDopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
Pezawas, L., Meyer-Lindenberg, A., Drabant, E. M., Verchinski, B. A., Munoz, K. E., Kolachana, B. S., Egan, M. F., Mattay, V. S., Hariri, A. R., & Weinberger, D. R. (2005) · Nature Neuroscience · doi:10.1038/nn1463 · Cited by 1,980
Self-citationLarge-scale recording of neuronal ensembles
Buzsáki, G. (2004) · Nature Neuroscience · doi:10.1038/nn1233 · Cited by 1,875
Self-citation
Research works printed but not linked: 1
- O'Donnell, P. & Grace, A. A. in Review of Psychiatry Vol 18: Schizophrenia in a Molecular Age. Ed. Tamminga, C. A. 109–140 (American Psychiatric Press, Washington DC, 1999).
Cited by
Items 101–200 of 241
Bianchi, M. T. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2007.09.012 · Cited by 40
Schwarz, A. J., Gass, N., Sartorius, A., Zheng, L., Spedding, M., Schenker, E., Risterucci, C., Meyer‐Lindenberg, A., & Weber‐Fahr, W. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.10.032 · Cited by 44
Self-citationPost-traumatic stress disorder: emerging concepts of pharmacotherapy
Baker, D. G., Nievergelt, C. M., & Risbrough, V. B. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902972494 · Cited by 40
Henry, J., & Włodkowic, D. (2020) · Behavioural Processes · doi:10.1016/j.beproc.2020.104226 · Cited by 38
Affective Biases in Humans and Animals
Robinson, E. S. J., & Roiser, J. P. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_5011 · Cited by 37
Haenisch, F., Alsaif, M., Guest, P. C., Rahmoune, H., Dickerson, F., Yolken, R. H., & Bahn, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.12.008 · Cited by 38
Rosiglitazone enhances learning, place cell activity, and synaptic plasticity in middle-aged rats
Wang, B. W., Hok, V., Della-Chiesa, A., Callaghan, C. K., Barlow, S. H., Tsanov, M., Bechara, R. G., Irving, E. A., Virley, D. J., Upton, N., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.013 · Cited by 37
Musazzi, L., Daniel, E. D., Maycox, P. R., Racagni, G., & Popoli, M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001240 · Cited by 41
Self-citationSzegedi, V., Juhász, G., Zhang, X., Barkóczi, B., Qi, H., Madeira, A., Kapus, G. L., Svenningsson, P., Spedding, M., & Penke, B. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.10.008 · Cited by 38
Self-citationTowards High-Throughput Chemobehavioural Phenomics in Neuropsychiatric Drug Discovery
Henry, J., & Włodkowic, D. (2019) · Marine Drugs · doi:10.3390/md17060340 · Cited by 36
Furuyashiki, T., & Kitaoka, S. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12901 · Cited by 37
Takahashi, K., Nakagawasai, O., Nemoto, W., Odaira, T., Arai, Y., Hisamitsu, T., & Tan–No, K. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.071 · Cited by 34
Repurposing Drugs via Network Analysis: Opportunities for Psychiatric Disorders
Truong, T. T. T., Panizzutti, B., Kim, J. H., & Walder, K. R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071464 · Cited by 37
Reconceptualizing major depressive disorder as an infectious disease
Canli, T. (2014) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-4-10 · Cited by 35
Rahman, M. M., Islam, M. R., Mim, S. A., Sultana, N., Chellappan, D. K., Dua, K., Kamal, M. A., Sharma, R., & Emran, T. B. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8425640 · Cited by 34
The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets
Lago, S. G., & Bahn, S. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00290-4 · Cited by 32
Chen, Y., Wang, H., Zhang, R., Wang, H., Peng, Z., Sun, R., & Tan, Q. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.11.038 · Cited by 31
Ganea, K., Menke, A., Schmidt, M. V., Lucae, S., Rammes, G., Liebl, C., Harbich, D., Sterlemann, V, Storch, C., Uhr, M., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.104 · Cited by 31
Lago, S. G., Tomasik, J., van Rees, G. F., Ramsey, J. M., Haenisch, F., Cooper, J. D., Broek, J. A., Suarez-Pinilla, P., Ruland, T., Auyeug, B., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0123-4 · Cited by 30
Lago, S. G., Tomasik, J., van Rees, G. F., Steeb, H., Cox, D., Rustogi, N., Ramsey, J. M., Bishop, J. A., Petryshen, T. L., Haggarty, S. J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau9093 · Cited by 30
DNA methylation in stress and depression: from biomarker to therapeutics
Sales, A. J., Guimarães, F. S., & Joca, S. R. L. (2021) · Acta Neuropsychiatrica · doi:10.1017/neu.2021.18 · Cited by 30
Peripheral mitochondrial DNA as a neuroinflammatory biomarker for major depressive disorder
Ye, J., Duan, C., Han, J., Chen, J., Sun, N., Li, Y., Yuan, T., & Peng, D. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01878 · Cited by 34
Han, F., Nakano, T., Yamamoto, Y., Shioda, N., Lu, Y., & Fukunaga, K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.02.014 · Cited by 25
Brady, L. S., Winsky, L., Goodman, W. K., Oliveri, M. E., & Stover, E. S. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.125 · Cited by 25
Shimada, T., Takai, Y., Shinohara, K., Yamasaki, A., Tominaga‐Yoshino, K., Ogura, A., Toi, A., Asano, K., Shintani, N., Hayata‐Takano, A., et al. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07724.x · Cited by 26
Chaudhari, S. B., Kumar, A., Mankar, V. H., Banerjee, S., Kumar, D., Mubarak, N. M., & Dehghani, M. H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32434 · Cited by 23
Niida, R., Yamagata, B., Matsuda, H., Niida, A., Uechi, A., Kito, S., & Mimura, M. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5009 · Cited by 25
Kleinloog, D., den Boogaard, A. U., Dahan, A., Mooren, R. A. G., Klaassen, E. S., Stevens, J., Freijer, J. I., & van Gerven, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115570082 · Cited by 26
A Data Mining Approach to In Vivo Classification of Psychopharmacological Drugs
Kafkafi, N., Yekutieli, D., & Elmer, G. I. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.103 · Cited by 22
Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia
Lago, S. G., & Bahn, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00205 · Cited by 25
Einat, H., Ezer, I., Kara, N. Z., & Belzung, C. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.14 · Cited by 23
van Rees, G. F., Lago, S. G., Cox, D., Tomasik, J., Rustogi, N., Weigelt, K., Özcan, S., Cooper, J. D., Drexhage, H. A., Leweke, F. M., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.10.003 · Cited by 22
Millan, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00001-1 · Cited by 23
Kortink, E. D., Weeda, W. D., Crowley, M. J., Moor, B. G., & van der Molen, M. J. W. (2018) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-018-0589-1 · Cited by 22
Toward Personalized Medicine in the Neuropsychiatric Field
Wong, E. H. F., Fox, J. C., Ng, M., & Lee, C. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387718-5.00013-4 · Cited by 21
Drugs in sport: a scientist–athlete's perspective: from ambition to neurochemistry
Spedding, M., & Spedding, C. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.163 · Cited by 22
Self-citationNewton, D. F., Oh, H., Shukla, R., Misquitta, K., Fee, C., Banasr, M., & Sibille, E. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.10.015 · Cited by 19
The Impaired Neurodevelopment of Human Neural Rosettes in HSV-1-Infected Early Brain Organoids
D’Aiuto, L., Caldwell, J. K., Wallace, C. T., Grams, T. R., Wesesky, M. A., Wood, J. A., Watkins, S. C., Kinchington, P. R., Bloom, D. C., & Nimgaonkar, V. L. (2022) · Cells · doi:10.3390/cells11223539 · Cited by 20
Zhu, H., Guan, J., Shi, J., Xu, P., Chang, S., Zhang, T., Feng, B., & Gu, J. (2019) · Journal of Separation Science · doi:10.1002/jssc.201900670 · Cited by 17
Liberg, B., Klauser, P., Harding, I. H., Adler, M., Rahm, C., Lundberg, J., Masterman, T., Wachtler, C., Jonsson, T., Wiberg, M. K., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00176 · Cited by 18
Cryan, J. F., Sánchez, C., Dinan, T. G., & Borsini, F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00007-2 · Cited by 17
Langer, E., Einat, H., & Stukalin, Y. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.04.007 · Cited by 18
Functional patient-derived cellular models for neuropsychiatric drug discovery
Lago, S. G., Tomasik, J., & Bahn, S. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01243-8 · Cited by 16
Chemistry-based molecular signature underlying the atypia of clozapine
Cardozo, T. J., Shmelkov, E., Felsövályi, K., Swetnam, J., Butler, T., Malaspina, D., & Shmelkov, S. V. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.6 · Cited by 16
A model of human endogenous retrovirus (HERV) activation in mental health and illness
Canli, T. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109404 · Cited by 16
Looking to the future of research in pediatric anxiety disorders
March, J. S. (2010) · Depression and Anxiety · doi:10.1002/da.20754 · Cited by 18
Analysis of Serotonin Molecules on Silver Nanocolloids—A Raman Computational and Experimental Study
Manciu, F. S., Ciubuc, J. D., Sundin, E. M., Qiu, C., & Bennet, K. E. (2017) · Sensors · doi:10.3390/s17071471 · Cited by 14
Therapeutic Armamentarium for Treating Depression
Howland, R. H. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2176 · Cited by 15
The chakragati mouse: A mouse model for rapid in vivo screening of antipsychotic drug candidates
Dawe, G. S., & Ratty, A. K. (2007) · Biotechnology Journal · doi:10.1002/biot.200700145 · Cited by 14
Simultaneous analysis of neuroactive compounds in zebrafishPreprint
Myers-Turnbull, D., Taylor, J. C., Helsell, C. V. M., McCarroll, M. N., Ki, C. S., Tummino, T. A., Ravikumar, S., Kinser, R., Gendelev, L., Alexander, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.01.891432 · Cited by 14
Féger, J., & Hirsch, É. C. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2014.10.001 · Cited by 15
Short-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry
Mulinari, S. (2023) · Big Data & Society · doi:10.1177/20539517221145680 · Cited by 13
Psychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia?
Catts, V. S., & Catts, S. V. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511789977.011 · Cited by 19
Zhao, X., & Dong, T. (2013) · Sensors · doi:10.3390/s131114570 · Cited by 14
Liu, C. C., Franaszczuk, P. J., Crone, N. E., Jouny, C. C., & Lenz, F. A. (2011) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2011.00080 · Cited by 15
Ryan, B. K., Anwyl, R., & Rowan, M. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.006 · Cited by 17
McArthur, R. A., & Borsini, F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00032-1 · Cited by 14
Zhang, Q., Wu, J., Pei, C., Ma, M., Dong, Y., Gao, M. J., & Zhang, H. (2022) · Biological Psychology · doi:10.1016/j.biopsycho.2022.108426 · Cited by 11
Network-based drug repurposing for psychiatric disorders using single-cell genomics
Gupta, C., Kalafut, N. C., Clarke, D., Choi, J. J., Arachchilage, K. H., Khullar, S., Xia, Y., Zhou, X., Dursun, C., Gerstein, M., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.101003 · Cited by 13
The specificity triad: notions of disease and therapeutic specificity in biomedical reasoning
Mulinari, S. (2014) · Philosophy Ethics and Humanities in Medicine · doi:10.1186/1747-5341-9-14 · Cited by 11
Lago, S. G., Tomasik, J., van Rees, G. F., Rustogi, N., Vázquez-Bourgón, J., Papiol, S., Suárez‐Pinilla, P., Crespo‐Facorro, B., & Bahn, S. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.03.016 · Cited by 10
Pharmacological MRI Approaches to Understanding Mechanisms of Drug Action
Minzenberg, M. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_177 · Cited by 10
Mining mouse behavior for patterns predicting psychiatric drug classification
Kafkafi, N., Mayo, C. L., & Elmer, G. I. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3230-6 · Cited by 9
Kim, Y., & Kim, S. (2023) · Psychiatry Investigation · doi:10.30773/pi.2022.0343 · Cited by 10
Bogachev, M. I., Lyanova, A. I., Sinitca, A., Анатольевна, П. С., Сергеевич, П. Н., Kuzmenko, A. V., Romanov, S., Brikova, O. I., Tsygankova, M., Ivkin, D. Y., et al. (2022) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2022.104409 · Cited by 8
Drug Discovery in Psychiatric Illness: Mining for Gold
Elmer, G. I., & Kafkafi, N. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn194 · Cited by 8
Drug development in pediatric psychiatry: current status, future trends
March, J. S., & Fegert, J. M. (2012) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-6-7 · Cited by 7
The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders
Gribkoff, V. K., & Kaczmarek, L. K. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-21054-9_11 · Cited by 8
Understanding Neurobehavioural Dynamics: A Close-Up View on Psychiatry and Quantum Mechanics
Latif, W. A., & Shadab, G. G. H. A. (2019) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2019.26.1.14 · Cited by 8
Mwangi, P. W., Wambugu, S. N., Kariuki, D., Mbugua, P. M., & Kanui, T. I. (2012) · Cited by 9
Mould-Quevedo, J. F., Contreras-Hernández, I., Verduzco, W., Mejía‐Aranguré, J. M., & Garduño‐Espinosa, J. (2009) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/s2173-5050(09)70041-x · Cited by 6
Modern Psychiatry: from Theory to Practice
Петрова, Н. Н. (2024) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2024-4-4-11-25 · Cited by 6
Herold, N. K., Gutsfeld, S., Leuthold, D., Wray, C., Spath, J., & Tal, T. L. (2025) · NeuroToxicology · doi:10.1016/j.neuro.2025.05.001 · Cited by 5
Thalamic post-inhibitory bursting occurs in patients with organic dystonia more often than controls
Kobayashi, K., Liu, C. C., Jensen, A. L., Vitek, J. L., Mari, Z. K., & Lenz, F. A. (2013) · Brain Research · doi:10.1016/j.brainres.2013.10.006 · Cited by 6
Portfolio Decisions in Early Development: Don’t Throw Out the Baby with the Bathwater
Herschel, M. B. (2012) · Pharmaceutical Medicine · doi:10.1007/bf03256895 · Cited by 5
Classification of Colon Cancer Patients Based on the Methylation Patterns of Promoters
Choi, W., Lee, J., Lee, J.-Y., Lee, S.-M., Kim, D.-W., & Kim, Y. (2016) · Genomics & Informatics · doi:10.5808/gi.2016.14.2.46 · Cited by 5
Antidepressants: past, present and future
Stein, D. J. (2012) · doi:10.2217/ebo.11.394 · Cited by 5
Selective-serotonin reuptake inhibitors
Wang, L. L., & Lam, R. W. M. (2012) · doi:10.2217/ebo.11.385 · Cited by 5
Minzenberg, M., & Carter, C. S. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.8.1029 · Cited by 5
Winsky, L., Driscoll, J., & Brady, L. S. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00002-3 · Cited by 6
Estes, M. L., Elmer, B. M., Carter, C., & McAllister, A. K. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/490466 · Cited by 6
Lim, H. D., Bartuzi, D., Keen, A. C., Rauffenbart, C., Glenn, J. R., Charlton, S. J., Lovera, S., Sands, Z. A., Ates, A., Wood, M. D., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00105 · Cited by 4
Schultz, J., Becker, B., Preckel, K., Seifert, M., Mielacher, C., Conrad, R., Kleiman, A., Maier, W., Kendrick, K. M., & Hurlemann, R. (2018) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2018.09.001 · Cited by 4
Spedding, M., Sebban, C., Jay, T. M., Rocher, C., Tesolin, B., Chazot, P. L., Schenker, E., Szénási, G., Lévay, G. I., Megyeri, K., et al. (2022) · Cells · doi:10.3390/cells11071181 · Cited by 4
Self-citationNeurosurgical Approaches to Therapeutic Brain Stimulation: For Treatment-Resistant Depression
Howland, R. H. (2008) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20080401-08 · Cited by 5
(2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2515 · Cited by 4
Mould-Quevedo, J. F., Contreras-Hernández, I., Verduzco, W., Mejía‐Aranguré, J. M., & Garduño‐Espinosa, J. (2009) · Revista de Psiquiatría y Salud Mental · doi:10.1016/s1888-9891(09)72401-2 · Cited by 3
The Potential Role of Exercise-Induced Neurotrophic Factors for Mental Health
Bırıncı, Y. Z. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106867 · Cited by 4
Animal Movement Pattern Model Identification based on Detrended Fluctuation Analysis
Lyanova, A. I., Grigarevichius, K. R., Sinitca, A., Kaplun, D., Sysoev, Y. I., & Bogachev, M. I. (2022) · International Multi-Conference on Engineering, Computer and Information Sciences (SIBIRCON) · doi:10.1109/sibircon56155.2022.10016985 · Cited by 3
Brain Development and CNS Plasticity
Fair, D. A., & Schlaggar, B. L. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0134-7_20 · Cited by 3
Surgical Treatment of Major Depression
Hamani, C., Snyder, B., Laxton, A. W., Holtzheimer, P. E., Mayberg, H. S., & Lozano, A. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5316-3.00091-5 · Cited by 3
Self-citationTroubles psychiatriques et ganglions de la base : une validation expérimentale
Féger, J., Worbe, Y., Galineau, L., & Tremblay, L. (2009) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2009.06.003 · Cited by 3
Noradrenergic and specific serotonergic antidepressants
Heck, E., & MacQUEEN, G. M. (2012) · doi:10.2217/ebo.11.227 · Cited by 3
Therapeutic potential of targeting gene variants in schizophrenia
Philibert, R. A., & Gershenfeld, H. K. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.7.757 · Cited by 3
Essential CNS drug development – pre-clinical development
Cross, A. J., & Yocca, F. D. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977640.004 · Cited by 4
Clinical Need and Rationale for Multi-Target Drugs in Psychiatry
Shahid, M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00014 · Cited by 2
Tripp, A. C., Kota, R. S., Lewis, D. A., & Sibille, E. L. (2010) · Cited by 2
Traditional Plant Compounds for the Treatment of Neuropsychiatric Disorders
Din, I., Anwar, M., Rayees, S., & Malik, F. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-1761-7_18 · Cited by 2
Alterations in Neural Structures as Risk Factors for Depression
Ramasubbu, R., & MacQUEEN, G. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-08-045078-0.00003-4 · Cited by 7
Kortink, E. D., Weeda, W. D., Verkuil, B., Topel, S., & van der Molen, M. J. W. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/2dfpa · Cited by 3
Metadata
- Authors
- Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., Popoli, M., Prochiantz, A., Richter-Levin, G., Somogyi, P., Spedding, M., Svenningsson, P., & Weinberger, D.
- Affiliations
- Inserm (FR)
- Rutgers, The State University of New Jersey (US)
- University of South Florida (US)
- National Hospital for Neurology and Neurosurgery (GB)
- National Institutes of Health (US)
- University of Pittsburgh (US)
- University of Dundee (GB)
- Emory University (US)
- University of Milan (IT)
- Centre National de la Recherche Scientifique (FR)
- Karolinska Institutet (SE)
- Corresponding author
- Spedding, Michael
- ORCID
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-03
- Volume
- 6
- Issue
- 3
- Pages
- 189-201
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2039643193
- Semantic Scholar
- 6b055b58cc82aab9331b179042a3985bb06b3e33
- Cited by
- 240
- References
- 81
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 12 · 2021: 7 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 3 · 2015: 8 · 2014: 10 · 2013: 17 · 2012: 30
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychiatric drug discovery, depression, schizophrenia, anxiety, neuropsychiatric disorders, neuroplasticity, translational neuroscience, multidisciplinary approach
- MeSH terms
- Mental Disorders, Consensus Statements as Topic, Humans, Models, Biological, Surveys and Questionnaires, Tranquilizing Agents, Drug Design, Signal Transduction, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.